Collegium Pharmaceutical, Inc. financials

  1. Home
  2. Financials
  3. COLL
COLL CIK 0001267565

Source: EDGAR filings · Built 2026-06-02T02:42:37Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 327.58M 203.33M 274.29M 122.61M 101.61M 88.40M
EBITDA 405.71M 339.06M 316.22M 36.00M 86.55M 117.78M
Working Capital 251.38M -27.25M 79.69M -13.74M 35.98M 38.44M
Net Debt 12.50M 173.42M 30.29M -24.59M -37.70M -65.05M
Gross Margin 59.35% 59.76% 57.55% 45.15% 54.40% 58.01%
Operating Margin 23.01% 26.91% 29.46% 7.18% 6.37% 18.14%
Net Margin 8.05% 10.96% 8.50% -5.39% 25.83% 8.63%
Return on Equity (ROE) 20.84% 30.23% 24.64% -12.83% 35.24% 14.38%
Return on Assets (ROA) 3.79% 4.16% 4.21% -2.13% 10.33% 4.16%
Current Ratio 1.57× 0.95× 1.17× 0.97× 1.13× 1.16×
Debt-to-Equity 0.81× 1.07× 1.38× 0.77× 0.73× 0.59×
Effective Tax Rate 32.12% 29.80% 36.41% 13.33% 2219.65% 3.01%
Cash Conversion Ratio 5.24× 2.96× 5.71× -4.97× 1.45× 3.51×
Accruals Ratio -0.16× -0.08× -0.20× -0.13× -0.05× -0.10×
SBC % of Revenue 5.37% 5.13% 4.79% 4.93% 8.76% 7.07%
CapEx Coverage 189.27× 124.08× 595.98× 76.59× 53.27× 16.94×
Free Cash Flow Per Share $8.25 $5.03 $6.56 $3.62 $2.48 $2.51

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 26.76× 15.40× 23.86× — 10.04× 26.36×
P/FCF 5.61× 5.70× 4.69× 6.40× 7.55× 7.97×
FCF Yield 17.82% 17.56% 21.32% 15.62% 13.25% 12.55%
EV / EBITDA 3.65× 3.17× 3.20× 21.13× 6.83× 5.33×
P/S 1.88× 1.43× 1.73× 1.69× 2.27× 2.24×
P/B 4.87× 3.94× 5.02× 4.03× 3.10× 3.73×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 780.57M 631.45M 566.77M 463.93M 276.87M 310.02M
Cost of Goods and Services Sold 317.31M 254.10M 240.60M 254.44M 126.25M 130.18M
Gross Profit 463.26M 377.34M 326.17M 209.49M 150.62M 179.84M
Research and Development Expense — 0 0 3.98M 9.45M 9.77M
Selling, General and Administrative Expense 284.80M 210.36M 159.21M 172.19M 118.96M 113.83M
Operating Expenses 283.62M 207.45M 159.21M 176.17M 132.99M 123.60M
Operating Income (Loss) 179.64M 169.90M 166.96M 33.32M 17.63M 56.23M
Income Tax Expense (Benefit) 29.75M 29.38M 27.58M -3.85M -74.89M 830.00K
Net Income (Loss) Attributable to Parent 62.87M 69.19M 48.16M -25.00M 71.52M 26.75M
Earnings Per Share, Basic $1.98 $2.14 $1.43 $-0.74 $2.05 $0.78
Weighted Average Number of Shares Outstanding, Basic 31.71M 32.27M 33.74M 33.83M 34.94M 34.41M
Earnings Per Share, Diluted $1.73 $1.86 $1.29 $-0.74 $1.86 $0.76
Weighted Average Number of Shares Outstanding, Diluted 39.70M 40.42M 41.79M 33.83M 41.05M 35.15M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 231.25M 70.56M 238.95M 173.69M 186.43M 174.12M
Assets, Current 691.41M 482.26M 537.60M 419.99M 315.54M 277.89M
Assets 1.66B 1.66B 1.14B 1.17B 692.08M 643.84M
Liabilities, Current 440.03M 509.51M 457.92M 433.73M 279.57M 239.45M
Liabilities 1.36B 1.43B 947.88M 979.29M 489.15M 457.81M
Stockholders' Equity Attributable to Parent 301.68M 228.84M 195.43M 194.84M 202.93M 186.03M
Common Stock, Shares, Outstanding 31.71M 31.44M 31.87M 33.85M 33.66M 34.61M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 329.32M 204.98M 274.75M 124.23M 103.56M 93.94M
Payments to Acquire Property, Plant, and Equipment 1.74M 1.65M 461.00K 1.62M 1.94M 5.55M
Net Cash Provided by (Used in) Investing Activities -63.53M -287.76M -70.81M -573.69M -1.94M -373.77M
Payments for Repurchase of Common Stock 25.10M 60.02M 75.00M 14.06M 47.86M —
Net Cash Provided by (Used in) Financing Activities -110.25M -60.60M -140.18M 436.72M -89.30M 286.47M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (COLL CIK 0001267565), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

WMK

WEIS MARKETS, INC

ENR

ENERGIZER HOLDINGS, INC.

NTNX

NUTANIX, INC.